PV Bulletin

IRIS guide to registration and RPIs

This updated guide details the process for registration and obtaining Research Product Identifiers (RPIs) within the IRIS system.

Primary source: European Medicines Agency

PV Impact Brief

Urgency: HighConfidence: high

What changed

The guide specifies that all submissions related to pharmacovigilance and safety in the EU must utilize the IRIS system for registration, with the requirement to request a new Research Product Identifier (RPI) if not already associated with an existing one.

Why it matters

Accurate registration and management of RPIs are essential for compliance with EU pharmacovigilance regulations, ensuring that organizations can effectively engage in safety monitoring and regulatory submissions.

Action needed

Organizations must establish an active EMA user account, ensure they have a valid EMA customer account number, and complete the SPOR/OMS registration process within five to ten working days if not previously registered.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Country ComplianceSignal Management
Owner

Regulatory Intelligence Lead

Review cadence

Review before 2026-06-15.

Policy change details

Document type
Procedural Guidance
Policy status
revised
Publication date
2026-06-15
Effective date
2026-06-15
Policy change
This updated guide details the process for registration and obtaining Research Product Identifiers (RPIs) within the IRIS system. RPIs are essential for identifying products across various regulatory procedures, including safety monitoring and clinical trial applications.

Key changes

Detailed steps for industry stakeholders to register their organizations and products in the IRIS platform to enable regulatory interactions.

Affected workflows

Country ComplianceSignal Management

Responsible groups

PV OperationsRegulatory Affairs

PV impact

Registration in IRIS is a prerequisite for all pharmacovigilance and safety-related submissions in the EU. Correct RPI management is critical for data integrity across PV databases.

View regulator source

Source document details

Exact policy details

EMA user account requirement
Must have an active EMA user account.
Applies to: All applicants including sponsors of Orphan Designation or acting on their behalf.
Section 1.1.1 · p. 4 · High · Source
Organisation registration in OMS timelines
The SPOR/OMS registration process takes five to ten working days.
Applies to: For organizations not already included in OMS.
Section 1.1.2 · p. 5 · High · Source
EMA customer account number requirement
Applicants must have a valid EMA Customer Account Number.
Applies to: For submissions, including parallel distribution notifications.
Section 1.1.3 · p. 5 · High · Source
Research Product Identifier (RPI)
Each new application must be associated with an existing RPI, or a new RPI must be requested.
Applies to: For scientific procedures in IRIS.
Section 1.1.4 · p. 5 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 15, 2026

Full briefing

Practical implication

Organizations must establish an active EMA user account, ensure they have a valid EMA customer account number, and complete the SPOR/OMS registration process within five to ten working days if not previously registered.

Registration in the IRIS system is now a prerequisite for all pharmacovigilance and safety-related submissions in the EU, effective from June 15, 2026. Proper management of RPIs is critical for maintaining data integrity across pharmacovigilance databases.

What changed: The guide specifies that all submissions related to pharmacovigilance and safety in the EU must utilize the IRIS system for registration, with the requirement to request a new Research Product Identifier (RPI) if not already associated with an existing one.

Why it matters: Accurate registration and management of RPIs are essential for compliance with EU pharmacovigilance regulations, ensuring that organizations can effectively engage in safety monitoring and regulatory submissions.

Practical implication: Organizations must establish an active EMA user account, ensure they have a valid EMA customer account number, and complete the SPOR/OMS registration process within five to ten working days if not previously registered.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward
publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Updated eCTD v4.0 technical validation criteria

Urgency: High

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Technical Guidance
Read impact briefarrow_forward